This is a translation of the original article in Portuguese. Read the original (Português).
A pill taken every day, AR1001, slowed the progression of Alzheimer’s over one year of clinical trials. The drug is made by the South Korean pharmaceutical company AriBio, and the data were presented at a conference in Boston, in the United States, according to the British newspaper Daily Mail.
According to the newspaper, patients who took the medication performed 31% better on memory tests and tests of everyday functions than those in the group that received a placebo, a substance with no effect. The study enrolled participants from 13 countries.
The number needs to be read with care. It is a comparison between two groups within a clinical trial, not a cure: the result indicates that the disease advanced more slowly among those who took the drug, not that it was stopped or reversed.
The format is one of the points that stands out. A daily pill would be simpler to use than the injectable treatments available today, which require administration and more frequent monitoring.
The topic carries weight for Brazil. Alzheimer’s weighs on families, who take on much of the caregiving, and on the health system, and the country is aging rapidly, which is likely to increase the number of cases in the coming years.
For now, AR1001 is a drug in the testing phase. The results were presented at a conference, and a medicine only reaches pharmacies after approval by the health authorities of each country. In Brazil, that review falls to Anvisa, the National Health Surveillance Agency. The company and the regulators still need to detail the next steps and the timeline for a possible registration.
Reporting from Daily Mail (p. 23, Boston/Estados Unidos: Novo comprimido para Alzheimer reduz declínio cognitivo em estudo).
Deixe um comentário